Literature DB >> 25511108

Esophageal cancer-related gene-4 (ECRG4) interactions with the innate immunity receptor complex.

Sonia Podvin1, Xitong Dang, Morgan Meads, Arwa Kurabi, Todd Costantini, Brian P Eliceiri, Andrew Baird, Raul Coimbra.   

Abstract

OBJECTIVE AND
DESIGN: The human c2orf40 gene encodes a tumor suppressor gene called esophageal cancer-related gene-4 (ECRG4) with pro- and anti-inflammatory activities that depend on cell surface processing. Here, we investigated its physical and functional association with the innate immunity receptor complex.
METHODS: Interactions between ECRG4 and the innate immunity receptor complex were assessed by flow cytometry, immunohistochemistry, confocal microscopy, and co-immunoprecipitation. Phage display was used for ligand targeting to cells that overexpress the TLR4-MD2-CD14.
RESULTS: Immunoprecipitation and immunohistochemical studies demonstrate a physical interaction between ECRG4 and TLR4-MD2-CD14 on human granulocytes. Flow cytometry shows ECRG4 on the cell surface of a subset of CD14(+) and CD16(+) leukocytes. In a cohort of trauma patients, the C-terminal 16 amino acid domain of ECRG4 (ECRG4(133-148)) appears to be processed and shed, presumably at a thrombin-like consensus sequence. Phage targeting this putative ligand shows that this peptide sequence internalizes into cells through the TLR4/CD14/MD2 complex, but modulates inflammation through non-canonical, NFκB signal transduction.
CONCLUSIONS: ECRG4 is present on the surface of human monocytes and granulocytes. Its interaction with the human innate immunity receptor complex supports a role for cell surface activation of ECRG4 during inflammation and implicates this receptor in its mechanism of action.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25511108      PMCID: PMC4301958          DOI: 10.1007/s00011-014-0789-2

Source DB:  PubMed          Journal:  Inflamm Res        ISSN: 1023-3830            Impact factor:   4.575


  58 in total

Review 1.  Evolving phage vectors for cell targeted gene delivery.

Authors:  David Larocca; Michael A Burg; Kristen Jensen-Pergakes; Edward Prenn Ravey; Ana Maria Gonzalez; Andrew Baird
Journal:  Curr Pharm Biotechnol       Date:  2002-03       Impact factor: 2.837

Review 2.  Gene transfer using targeted filamentous bacteriophage.

Authors:  D Larocca; K Jensen-Pergakes; M A Burg; A Baird
Journal:  Methods Mol Biol       Date:  2002

3.  Role of EGF receptor transactivation in phosphoinositide 3-kinase-dependent activation of MAP kinase by GPCRs.

Authors:  Bukhtiar H Shah; Adrienne Neithardt; David B Chu; Farzana B Shah; Kevin J Catt
Journal:  J Cell Physiol       Date:  2006-01       Impact factor: 6.384

4.  Esophageal cancer related gene 4 (ECRG4) is a marker of articular chondrocyte differentiation and cartilage destruction.

Authors:  Yun Hyun Huh; Je-Hwang Ryu; Sun Shin; Dong-Uk Lee; Siyoung Yang; Kyung-Shin Oh; Churl-Hong Chun; Jeong-Keun Choi; Woo Keun Song; Jang-Soo Chun
Journal:  Gene       Date:  2009-09-06       Impact factor: 3.688

5.  Functional heterogeneity and differential priming of circulating neutrophils in human experimental endotoxemia.

Authors:  Janesh Pillay; Bart P Ramakers; Vera M Kamp; Adele Lo Tam Loi; Siu W Lam; Falco Hietbrink; Luke P Leenen; Anton T Tool; Peter Pickkers; Leo Koenderman
Journal:  J Leukoc Biol       Date:  2010-04-16       Impact factor: 4.962

6.  RGS16 function is regulated by epidermal growth factor receptor-mediated tyrosine phosphorylation.

Authors:  A Derrien; K M Druey
Journal:  J Biol Chem       Date:  2001-10-15       Impact factor: 5.157

7.  Innate immunity triggers oligodendrocyte progenitor reactivity and confines damages to brain injuries.

Authors:  Isaias Glezer; Amelie Lapointe; Serge Rivest
Journal:  FASEB J       Date:  2006-02-07       Impact factor: 5.191

8.  Expression of esophageal cancer related gene 4 (ECRG4), a novel tumor suppressor gene, in esophageal cancer and its inhibitory effect on the tumor growth in vitro and in vivo.

Authors:  Lin-Wei Li; Xi-Ying Yu; Yang Yang; Chun-Peng Zhang; Li-Ping Guo; Shih-Hsin Lu
Journal:  Int J Cancer       Date:  2009-10-01       Impact factor: 7.396

9.  Ecrg4 expression and its product augurin in the choroid plexus: impact on fetal brain development, cerebrospinal fluid homeostasis and neuroprogenitor cell response to CNS injury.

Authors:  Ana Maria Gonzalez; Sonia Podvin; Shuh-Yow Lin; Miles C Miller; Hannah Botfield; Wendy E Leadbeater; Andrew Roberton; Xitong Dang; Stuart E Knowling; Elena Cardenas-Galindo; John E Donahue; Edward G Stopa; Conrad E Johanson; Raul Coimbra; Brian P Eliceiri; Andrew Baird
Journal:  Fluids Barriers CNS       Date:  2011-01-18

10.  Peptidome analysis of cerebrospinal fluid by LC-MALDI MS.

Authors:  Mikko Hölttä; Henrik Zetterberg; Ekaterina Mirgorodskaya; Niklas Mattsson; Kaj Blennow; Johan Gobom
Journal:  PLoS One       Date:  2012-08-06       Impact factor: 3.240

View more
  12 in total

1.  Monitoring Neutrophil-Expressed Cell Surface Esophageal Cancer Related Gene-4 after Severe Burn Injury.

Authors:  Todd W Costantini; Raul Coimbra; Nicole E Lopez; Jeanne G Lee; Bruce Potenza; Alan Smith; Andrew Baird; Brian P Eliceiri
Journal:  Surg Infect (Larchmt)       Date:  2015-10-13       Impact factor: 2.150

2.  Open reading frame mining identifies a TLR4 binding domain in the primary sequence of ECRG4.

Authors:  Xitong Dang; Raul Coimbra; Liang Mao; Sonia Podvin; Xue Li; Hua Yu; Todd W Costantini; Xiaorong Zeng; Dana Larocca; Brian P Eliceiri; Andrew Baird
Journal:  Cell Mol Life Sci       Date:  2019-06-12       Impact factor: 9.261

3.  The Orphan C2orf40 Gene is a Neuroimmune Factor in Alzheimer's Disease.

Authors:  Sonia Podvin; Miles C Miller; Ryan Rossi; Jasmine Chukwueke; John E Donahue; Conrad E Johanson; Andrew Baird; Edward G Stopa
Journal:  JSM Alzheimers Dis Relat Dement       Date:  2016-04-01

4.  Soluble purified recombinant C2ORF40 protein inhibits tumor cell growth in vivo by decreasing telomerase activity in esophageal squamous cell carcinoma.

Authors:  Linwei Li; Xiaoyan Li; Wenyu Wang; Tianhui Gao; Yun Zhou; Shixin Lu
Journal:  Oncol Lett       Date:  2016-08-02       Impact factor: 2.967

5.  Down-regulated ECRG4 expression in breast cancer and its correlation with tumor progression and poor prognosis--A short Report.

Authors:  Yanjie You; Haijun Li; Xin Qin; Yonggang Ran; Fei Wang
Journal:  Cell Oncol (Dordr)       Date:  2015-12-02       Impact factor: 6.730

Review 6.  ECRG4: a new potential target in precision medicine.

Authors:  Xin Qin; Ping Zhang
Journal:  Front Med       Date:  2018-07-12       Impact factor: 4.592

7.  A short synthetic peptide fragment of human C2ORF40 has therapeutic potential in breast cancer.

Authors:  Chaoyang Li; Pengju Zhang; Anli Jiang; Jian-Hua Mao; Guangwei Wei
Journal:  Oncotarget       Date:  2017-06-27

8.  Ecrg4 peptide is the ligand of multiple scavenger receptors.

Authors:  Tetsuo Moriguchi; Shuji Takeda; Shinzo Iwashita; Kei Enomoto; Tatsuya Sawamura; Uichi Koshimizu; Toru Kondo
Journal:  Sci Rep       Date:  2018-03-06       Impact factor: 4.379

9.  ECRG4 expression in normal rat tissues: expression study and literature review.

Authors:  A Porzionato; M Rucinski; V Macchi; G Sarasin; L K Malendowicz; R De Caro
Journal:  Eur J Histochem       Date:  2015-05-18       Impact factor: 3.188

10.  Downregulation and DNA methylation of ECRG4 in gastric cancer.

Authors:  Peng Deng; Xiao-Jing Chang; Zi-Ming Gao; Xiao-Yang Xu; An-Qi Sun; Kai Li; Dong-Qiu Dai
Journal:  Onco Targets Ther       Date:  2018-07-13       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.